Researchers have successfully used CRISPR gene editing to permanently lower cholesterol levels in patients with familial hypercholesterolemia, a genetic condition that causes dangerously high cholesterol. In a clinical trial published in The New England Journal of Medicine, patients who received the highest dose saw their LDL cholesterol (the "bad" kind) drop by 49% and triglycerides fall by 55% after a single treatment .

How Does Gene Editing Lower Cholesterol?

The experimental treatment uses CRISPR, a gene-editing tool often described as biological scissors, to make precise cuts in DNA. Specifically, the therapy targets a liver gene called ANGPTL3 that normally prevents the body from clearing lipids (fatty substances including LDL cholesterol and triglycerides) from the bloodstream. By turning off this gene, the liver can finally remove excess cholesterol and triglycerides, allowing blood lipid levels to fall dramatically .

This approach builds on decades of research into why some families naturally have extraordinarily low cholesterol levels. Scientists discovered that certain people have key liver genes either dialed down or turned off entirely, protecting them from heart disease without any negative health effects .

Why Would a One-Time Treatment Change Everything?

The real excitement around this therapy stems from a persistent problem in heart disease prevention: most patients simply don't take their cholesterol medications consistently. Current cholesterol-lowering drugs require lifelong use, but research shows that between 25% to 50% of statin users stop taking them within one year. Even more striking, more than 50% of heart attack survivors quit their statins within two years, despite medical advice to take them for life .

A one-time gene-editing treatment could eliminate this adherence problem entirely. Instead of remembering to take pills every day, patients would receive a single therapy that permanently lowers their cholesterol.

"I love the idea of one and done. Durably lowering cholesterol for the rest of your life could be transformational for some patients," said Dr. Priscilla Hsue, chief of the cardiology division at UCLA Health.

Dr. Priscilla Hsue, Chief of Cardiology at UCLA Health

What Do the Real-World Results Look Like?

The trial involved 15 participants, including Christos Soteriou, a 51-year-old from South Australia who had familial hypercholesterolemia, a genetic condition that caused him to need a quadruple bypass surgery at just 29 years old. Despite taking statins and newer cholesterol drugs like Repatha, nothing had worked to adequately lower his cholesterol. After receiving the CRISPR treatment, his cholesterol levels dropped to their lowest point ever, shocking even his cardiologists .

Another trial participant, Marco Carabott, 54, had struggled with medication adherence for years before suffering a heart attack and requiring the same bypass surgery. For him, the promise of a one-time treatment represented a chance to finally protect his heart without relying on daily pills .

Steps to Understanding Gene-Editing Therapies for Heart Health

• Current Cholesterol Medications: Patients have access to statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors, which block a protein that prevents the liver from removing cholesterol from the blood.
• The Adherence Challenge: Between 25% to 50% of statin users stop taking them within one year, and over 50% of heart attack survivors quit within two years despite medical recommendations.
• Gene-Editing Approach: CRISPR therapy targets the ANGPTL3 gene in the liver to allow the body to naturally clear excess cholesterol and triglycerides from the bloodstream.
• Trial Results: Patients receiving the highest dose experienced a 49% reduction in LDL cholesterol and a 55% reduction in triglycerides after a single treatment.

When Could This Treatment Become Available?

While the initial results are exciting, larger and longer trials are still underway. Dr. Kiran Musunuru, a professor of medicine at the University of Pennsylvania who co-founded Verve Therapeutics to develop this technology, believes gene-editing treatments could become available by the early 2030s for specific patient groups, such as people recovering from a heart attack .

"Before they leave the hospital, they get this one-time therapy that permanently reduces their cholesterol levels. They're protected from that next heart attack," explained Dr. Kiran Musunuru, professor of medicine at the University of Pennsylvania.

Dr. Kiran Musunuru, Professor of Medicine at the University of Pennsylvania

Musunuru envisions an even broader future where the treatment could eventually be given to high-risk groups like people with Type 2 diabetes, or even administered in early adulthood as lifelong protection against heart disease. He estimates that if enough people received this therapy at age 20, it could improve overall life expectancy by preventing heart attacks entirely .

However, safety must be guaranteed first. Researchers are carefully monitoring long-term effects and how well the treatment works across different patient populations before expanding its use beyond clinical trials.

What About Other Gene-Editing Approaches?

The ANGPTL3 approach isn't the only gene-editing strategy being explored. Verve Therapeutics is also running trials using CRISPR to inactivate a different gene called PCSK9 in people with familial hypercholesterolemia or coronary artery disease. Preliminary data from that trial shows significant reductions in LDL cholesterol as well .

Gene editing has already proven transformative for rare genetic diseases like sickle cell disease and beta thalassemia. Using it for more common conditions like high cholesterol represents a significant expansion of the technology's potential impact on public health .

"I still get a message once every couple weeks from physicians saying, 'My patients saw this on TV and they want to do this,'" said Dr. Luke Laffin, the trial's lead investigator and a preventative cardiologist at the Cleveland Clinic.

Dr. Luke Laffin, Preventative Cardiologist at the Cleveland Clinic

The cholesterol gene-editing trial represents a paradigm shift in how cardiologists think about preventing heart disease. Rather than asking patients to take medications for decades, researchers are exploring ways to permanently alter the biology that causes high cholesterol in the first place. While much work remains before these therapies reach patients, the early results suggest that one-time genetic treatments could soon transform heart disease prevention from a lifelong medication burden into a single, permanent solution.